|
The CRC for Diagnostics officially ceased operations in September 2007 |
Some of the research programs formed the basis of a new CRC for Biomarker Translation.
The new CRC will develop antibody-based therapeutics and diagnostic tests that target cell surface molecules (biomarkers) expressed by white blood cells or cancer cells. These antibodies or “magic bullets" target the cells involved in major diseases, including autoimmune disease and cancers. The new therapies and tests are expected to transform the management of these diseases and make Australia a competitive force in the rapidly growing, multi-billion dollar antibody therapeutic market.
For further details, contact Professor Mark Hogarth Tel +61 03 9287 0685 or email pmhogarth@burnet.edu.au
|
